REGN Deadline: REGN Investors with Losses in Excess of $100K Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
NEW YORK, March 2, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023


